Home > Newsletters > Drug Industry Daily > Final Six-Month Spending Bill Likely to Neglect Generic, Biosimilar Fees
Drug Industry Daily
Sept. 17, 2012 | Vol. 11 No. 182
Final Six-Month Spending Bill Likely to Neglect Generic, Biosimilar Fees
The Senate is unlikely to alter a House-approved continuing resolution that will keep the FDA and federal government open through March 27, leaving the agency without permission to collect the newly created generic and biosimilar user fees.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.